Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3204693 | 1.00 | GRM4 (0.49) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL3198793 | 0.89 | POLB (0.50) | MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3198785 | 0.89 | POLB (0.50) | MEN1KMT2AALDH1A1TDP1 | |
| SCHEMBL3189087 | 0.88 | GAA (0.46) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL3189096 | 0.88 | GAA (0.46) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL13483364 | 0.88 | GAA (0.46) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL3187241 | 0.88 | GRM4 (0.46) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL3187226 | 0.88 | GRM4 (0.46) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL14494336 | 0.85 | GRM4 (0.40) | GRM4GRM1GAAMEN1KMT2A | |
| SCHEMBL5511033 | 0.83 | GRM4 (0.54) | GRM4GRM1GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | claimed |
| EP-1379249-A4 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2008-01-09 | — | — | EP | claimed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | claimed |
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-06 | — | — | US | claimed |
| EP-1379249-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-01-14 | — | — | EP | claimed |
| WO-2002067939-A1 | FUSED CYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-06 | — | — | WO | claimed |
| US-7655688-B2 | Treating nuclear hormone receptor-associated conditions such as cancer and immune disorders; (3a alpha ,4 alpha ,7 alpha ,7a alpha )-2-(3-Chloro-4-hydroxyphenyl)hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-02 | — | — | US | disclosed |
| US-7230058-B2 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7230058-B2 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7230058-B2 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7157523-B2 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157523-B2 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157523-B2 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20060189771-A1 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2006-05-25 | — | — | US | disclosed |
| US-20060041092-A1 | Ring-opened polynorbornenes | JSR CORPORATION (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1561766-A1 | RING-OPENED POLYNORBORNENES | JSR Corporation (JP) | 2005-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087548-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | GRM4 237/4885GRM1 302/4885GAA 4211/4885 |
| US-20060111424-A1 | Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, ESRRA, NR5A1 | GRM4 237/4885GRM1 302/4885GAA 4211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.